The prevalence of obesity has increased dramatically in recent decades, both in the US and
worldwide. Pharmacotherapy can augment the weight-reducing effects of lifestyle …

Introduction: The dramatic rise in the prevalence of obesity and type 2 diabetes mellitus
(T2DM) is associated with increased mortality, morbidity as well as public health care …

The aim of the work was to investigate whether continuation of treatment, side effects, and
effect on weight loss of GLP-1 agonists in obese patients without diabetes are equally …

Purpose Published data on the weight loss effects of glucagon-like peptide 1 (GLP-1)
receptor agonists are reviewed, with a focus on data from clinical trials. Summary Obesity is …

Obesity is a chronic disease requiring chronic management. Anti-obesity medication for the
treatment of obesity includes the glucagon-like peptide-1 (GLP-1) agonists liraglutide and …

Purpose The efficacy and safety of glucagon-like peptide (GLP)-1 receptor agonists for
weight loss in adult patients without diabetes is reviewed. Summary GLP-1 receptor agonists …

Incretin-based therapies (subcutaneously administered glucagon-like peptide-1 [GLP-1]
agonists and oral dipeptidyl peptidase-4 inhibitors) represent a new mechanism of action …

Objective The role of glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of
type 2 diabetes is debated; many recent trials, which were not included in previous meta …

Abstract Introduction Glucagon-like peptide-1 (GLP-1) has been the focus of considerable
research activity in the treatment of type 2 diabetes mellitus (T2DM) because the incretin …

Recently incretin-based therapies have been developed in the clinical practice, this class
includes both the dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, vildagliptin …